Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 18:20:39时区推断·⟳ 抓取 18:21:33·⚡ 决策 08-04 18:41:54 +20m21s·83.9 天前
SOPHiA GENETICS与阿斯利康开展多年伴随诊断合作
SOPHiA GENETICS称将与阿斯利康推进两个精准肿瘤伴随诊断项目，覆盖实体瘤应用和血液肿瘤应用。
📄 原文Investing.com↗ 原文
SOPHiA GENETICS partners with AstraZeneca on diagnostics
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets BOSTON and ROLLE, Switzerland - SOPHiA GENETIC…
不做 SOPHiA GENETICS（SOPH.US）
合作方向偏正面但未披露金额、经济权益和商业化节奏，且AZN合作并非新客户突破；当日Q2财报即将披露，当前不做。
不做 阿斯利康（AZN.US）
对阿斯利康体量过小且未披露财务影响，不构成市值级短线催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- SOPHiA与阿斯利康早在2023年已扩展精准肿瘤多模态合作，说明AZN关系不是全新客户突破。
- 公司曾公告与阿斯利康扩展MSK-ACCESS液体活检部署，合作链条此前已有传播。
- Investing转述SOPHiA与阿斯利康开展两个伴随诊断项目的多年合作，但未披露金额。市场反应:行情工具显示盘前参考价5.70美元，较前收5.64美元涨1.06%。
- 公司IR页面显示当日将举行Q2 2026业绩电话会，短线交易将面临财报主导风险。
关键理由
- SOPHiA GENETICS称将与阿斯利康推进两个精准肿瘤伴随诊断项目，覆盖实体瘤应用和血液肿瘤应用。
- 公司2025年收入约7730万美元、2026年指引9200万-9400万美元；若CDx合作最终商业化，理论上对约4.77亿美元市值的小公司有弹性，但本条未披露金额、里程碑付款、分成或上市时间。
- 阿斯利康合作并非全新关系，SOPHiA在2023、2025年已有多次与AZN扩展合作公告，本次更像项目延伸而非可立即量化订单。
主要风险
- 未披露合同金额和经济权益，无法估算短期收入或现金流增量。
- 公司仍亏损，Q1 2026净亏损1930万美元、现金6539万美元，且Q2 2026财报电话会就在2026-08-04 08:00 ET，财报风险会主导开盘交易。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中当前AZN伴随诊断合作的独立量化解读或收入测算。
检索:SOPHiA GENETICS AstraZeneca companion diagnostics collaboration revenue diagnostics oncology bearish cash burn - 做多前查反向 · 来源 web · 日期 2023-02-13/2025-04-28 · 影响 weakens
公司此前已有多次AZN合作扩展，本条更像既有合作延伸，预期差有限。
检索:SOPHiA GENETICS AstraZeneca partnership prior collaboration 2023 2025 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-05-05 · 影响 weakens
IR页面显示Q2财报会在当日08:00 ET，开盘前可能出现更强财报信息，压过合作新闻。
检索:SOPHiA GENETICS Q2 2026 earnings August 4 2026 原文 ↗
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 1,954 字
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
BOSTON and ROLLE, Switzerland - SOPHiA GENETICS (NASDAQ:SOPH) announced today a multi-year collaboration with AstraZeneca (LSE/STO/NYSE:AZN) to develop and deploy two companion diagnostics for precision oncology therapies.
The agreement will advance two companion diagnostic programs, according to a press release statement. SOPHiA GENETICS will develop its Solid Tumor application into a decentralized companion diagnostic and will develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer.
The collaboration will combine SOPHiA GENETICS’s decentralized clinical trial assays and companion diagnostic capabilities with AstraZeneca therapies. The programs aim to enable laboratories to conduct standardized testing across different geographic locations.
"A breakthrough therapy only matters to the patients we can find in time to treat," said Ross Muken, CEO of SOPHiA GENETICS. "We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch."
SOPHiA GENETICS operates a cloud-based platform that connects more than 1,000 institutions across over 75 countries. The platform allows healthcare institutions to run validated analysis locally while sharing data across the network.
The company’s diagnostic capabilities include clinical trial assay development for patient identification and enrollment, companion diagnostic development and regulatory submission for approval in the U.S., EU, and Japan, and deployment through its SOPHiA DDM Platform and MaxCare Program.
The collaboration will focus on biomarker detection and deployment to support clinical decision-making across healthcare systems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOSTON and ROLLE, Switzerland - SOPHiA GENETICS (NASDAQ:SOPH) announced today a multi-year collaboration with AstraZeneca (LSE/STO/NYSE:AZN) to develop and deploy two companion diagnostics for precision oncology therapies.
The agreement will advance two companion diagnostic programs, according to a press release statement. SOPHiA GENETICS will develop its Solid Tumor application into a decentralized companion diagnostic and will develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer.
The collaboration will combine SOPHiA GENETICS’s decentralized clinical trial assays and companion diagnostic capabilities with AstraZeneca therapies. The programs aim to enable laboratories to conduct standardized testing across different geographic locations.
"A breakthrough therapy only matters to the patients we can find in time to treat," said Ross Muken, CEO of SOPHiA GENETICS. "We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch."
SOPHiA GENETICS operates a cloud-based platform that connects more than 1,000 institutions across over 75 countries. The platform allows healthcare institutions to run validated analysis locally while sharing data across the network.
The company’s diagnostic capabilities include clinical trial assay development for patient identification and enrollment, companion diagnostic development and regulatory submission for approval in the U.S., EU, and Japan, and deployment through its SOPHiA DDM Platform and MaxCare Program.
The collaboration will focus on biomarker detection and deployment to support clinical decision-making across healthcare systems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。